FDA approves Lilly's ADHD drug Strattera
Eli Lilly has won FDA approval of Strattera, a therapy designed to treat ADHD. Lilly says this is the first regulatory win for a non-stimulant ADHD drug in a market dominated by two stimulants--Adderall (Shire) and Ritalin (Novartis). And researchers say that the data indicates the drug works past the 3 o'clock bell and into the evening.
There is a slight increase of suicidal thoughts for children and teens in the data; .4 percent in the Strattera group compared to none in the control group. In adults there was no discernible increase in suicidal thoughts.
"The approval provides physicians and their patients with the first treatment option that is indicated for maintenance of ADHD" said Thomas J. Spencer, M.D., Associate Professor of Psychiatry, Harvard Medical School. "This is critical as ADHD may be a life-long disease and effective long-term control of symptoms may mean improved outcomes in children and adolescents."
- check out the press release
- read the AP report
Related Articles:
Lilly beset by potential Strattera imitators
Lilly sues Sun Pharma to protect Strattera
Feds to study ADHD drugs for heart risks
Comments (1) | Post a comment Rate it:
More stories about Eli Lilly Strattera ADHD Thomas J. Spencer Harvard Medical School FDA approval Adderall
Comments
By Anonymous | Posted 11:17am | May 9, 2008
FDA approves... for maintenance therapy.
Strattera has been on the market for several years - this maintenance therapy indication, however, is new.
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight